Prof Alessandro Rambaldi speaks to ecancer at ASH 2018 about the phase 2 study looking into blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-NHL.
He explains that although the frontline treatment for NHL is very effective, the outcome for those who relapse is poor, hence the need for a second salvage therapy.
Prof Rambaldi reports that treatment with blinatumomab achieved a 37% overall response and that these patients could go on to receive an autologous stem cell transplant.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.